Subscribe to Journal
Get full journal access for 1 year
only $3.90 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
Fischer, K. R. et al. Epithelial-to-mesenchymal transition is not required for lung metastasis but contributes to chemoresistance. Nature 527, 472–476 (2015)
Tan, T. Z. et al. Epithelial-mesenchymal transition spectrum quantification and its efficacy in deciphering survival and drug responses of cancer patients. EMBO Mol. Med. 6, 1279–1293 (2014)
Ye, X. et al. Distinct EMT programs control normal mammary stem cells and tumour-initiating cells. Nature 525, 256–260 (2015)
Nieto, M. A., Huang, R. Y., Jackson, R. A. & Thiery, J. P. EMT: 2016. Cell 166, 21–45 (2016)
Cano, A. et al. The transcription factor snail controls epithelial-mesenchymal transitions by repressing E-cadherin expression. Nat. Cell Biol. 2, 76–83 (2000)
Batlle, E. et al. The transcription factor snail is a repressor of E-cadherin gene expression in epithelial tumour cells. Nat. Cell Biol. 2, 84–89 (2000)
Comijn, J. et al. The two-handed E box binding zinc finger protein SIP1 downregulates E-cadherin and induces invasion. Mol. Cell 7, 1267–1278 (2001)
Bolós, V. et al. The transcription factor Slug represses E-cadherin expression and induces epithelial to mesenchymal transitions: a comparison with Snail and E47 repressors. J. Cell Sci. 116, 499–511 (2003)
Yang, J. et al. Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis. Cell 117, 927–939 (2004)
Yu, M. et al. Circulating breast tumor cells exhibit dynamic changes in epithelial and mesenchymal composition. Science 339, 580–584 (2013)
Grande, M. T. et al. Snail1-induced partial epithelial-to-mesenchymal transition drives renal fibrosis in mice and can be targeted to reverse established disease. Nat. Med. 21, 989–997 (2015)
Ocaña, O. H. et al. Metastatic colonization requires the repression of the epithelial-mesenchymal transition inducer Prrx1. Cancer Cell 22, 709–724 (2012)
Tsai, J. H., Donaher, J. L., Murphy, D. A., Chau, S. & Yang, J. Spatiotemporal regulation of epithelial-mesenchymal transition is essential for squamous cell carcinoma metastasis. Cancer Cell 22, 725–736 (2012)
Tran, H. D. et al. Transient SNAIL1 expression is necessary for metastatic competence in breast cancer. Cancer Res. 74, 6330–6340 (2014)
Beerling, E. et al. Plasticity between epithelial and mesenchymal states unlinks EMT from metastasis-enhancing stem cell capacity. Cell Reports 14, 2281–2288 (2016)
Okada, H., Danoff, T. M., Kalluri, R. & Neilson, E. G. Early role of Fsp1 in epithelial-mesenchymal transformation. Am. J. Physiol. 273, F563–F574 (1997)
Österreicher, C. H. et al. Fibroblast-specific protein 1 identifies an inflammatory subpopulation of macrophages in the liver. Proc. Natl Acad. Sci. USA 108, 308–313 (2011)
Xue, C., Plieth, D., Venkov, C., Xu, C. & Neilson, E. G. The gatekeeper effect of epithelial-mesenchymal transition regulates the frequency of breast cancer metastasis. Cancer Res. 63, 3386–3394 (2003)
Korpal, M. et al. Direct targeting of Sec23a by miR-200s influences cancer cell secretome and promotes metastatic colonization. Nat. Med. 17, 1101–1108 (2011)
Ni, T. et al. Snail1-dependent p53 repression regulates expansion and activity of tumour-initiating cells in breast cancer. Nat. Cell Biol. 18, 1221–1232 (2016)
R.A.W. is listed as an inventor on three patent applications filed by the Whitehead Institute for Biomedical Research relating to the formation of cancer stem cells through activation of an EMT program. US patent application number US 14/441,697 describes a method to use PKCa/FRA1 pathway inhibitors to target carcinoma cells that are identified by their increased expression of EMT-related genes. US patent application number US 15/307,657 describes a method to induce cancer stem cells to undergo EMT, rendering them amenable to conventional treatments. US patent application number US 14/065,311 describes methods for identifying compounds and compositions that target cancer stem cells, including cancer stem cells that have undergone EMT. R.A.W. is also listed as an inventor on two related patents that have been granted. US patent number US9212347 describes methods for preparing progenitor cells by inducing EMT. US patent number US9308238 describes methods and compounds for modulating and inducing EMT. R.A.W. is also a cofounder of Verastem Inc.
Extended data figures and tables
a–d, DAPI nuclear staining is shown in blue. Anti-cytokeratin staining is shown in grey. Snail-expressing cells are marked by anti-YFP staining in green (a, b). Anti-Zeb1 staining is shown in green (c, d). Anti-Fsp1 (a, c) and anti-Vim (b, d) staining are shown in red. Arrows indicate cytokeratin-positive tumour cells that express either the Snail (a, b) or the Zeb1 (c, d) EMT transcription factor but, at the same time, lack evident Fsp1 (a, c) or Vim (b, d) expression. Scale bars, 20 μm.
About this article
Cite this article
Ye, X., Brabletz, T., Kang, Y. et al. Upholding a role for EMT in breast cancer metastasis. Nature 547, E1–E3 (2017). https://doi.org/10.1038/nature22816
So alike yet so different. Differential expression of the long non-coding RNAs NORAD and HCG11 in breast cancer subtypes
Genetics and Molecular Biology (2021)
Breast cancer as an example of tumour heterogeneity and tumour cell plasticity during malignant progression
British Journal of Cancer (2021)
International Journal of Molecular Sciences (2021)
Benzimidazole-Based Organic–Inorganic Gold Nanohybrids Suppress Invasiveness of Cancer Cells by Modulating EMT Signaling Cascade
ACS Applied Bio Materials (2021)
Developmental Cell (2021)